Journal of Crohn's and Colitis
Volume 6, Issue 1 , Pages 1-12 , February 2012

The effect of smoking on intestinal inflammation: What can be learned from animal models?

Received 26 August 2011 ,Revised 11 September 2011 ,Accepted 12 September 2011.

References 

  1. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed). 1982;284:706
  2. Benoni C, Nilsson A. Smoking habits in patients with inflammatory bowel disease. Scand J Gastroenterol. 1984;19:824–830
  3. Bernstein CN. New insights into IBD epidemiology: are there any lessons for treatment?. Dig Dis. 2010;28:406–410
  4. Carbonnel F, Jantchou P, Monnet E, Cosnes J. Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroenterol Clin Biol. 2009;33(Suppl. 3):S145–S157
  5. Reif S, Lavy A, Keter D, Fich A, Eliakim R, Halak A, et al. Lack of association between smoking and Crohn's disease but the usual association with ulcerative colitis in Jewish patients in Israel: a multicenter study. Am J Gastroenterol. 2000;95:474–478
  6. Reif S, Klein I, Arber N, Gilat T. Lack of association between smoking and inflammatory bowel disease in Jewish patients in Israel. Gastroenterology. 1995;108:1683–1687
  7. Jones DT, Osterman MT, Bewtra M, Lewis JD. Passive smoking and inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103:2382–2393
  8. Karban A, Eliakim R. Effect of smoking on inflammatory bowel disease: is it disease or organ specific?. World J Gastroenterol. 2007;13:2150–2152
  9. Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm Bowel Dis. 2004;10:848–859
  10. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflamm Res. 2008;57:497–503
  11. Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, and colorectal cancer survival: the Seattle Colon Cancer Family Registry. Cancer. Apr 14 2011;published online. (Epub ahead of print)
  12. Ng SC, Woodrow S, Patel N, Subhani J, Harbord M. Role of genetic and environmental factors in British twins with inflammatory bowel disease. Inflamm Bowel Dis. May 6 2011;published online. (Epub ahead of print)
  13. Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. Eur J Gastroenterol Hepatol. 2002;14:607–614
  14. Eliakim R, Karmeli F, Cohen P, Heyman SN, Rachmilewitz D. Dual effect of chronic nicotine administration: augmentation of jejunitis and amelioration of colitis induced by iodoacetamide in rats. Int J Colorectal Dis. 2001;16:14–21
  15. Eliakim R, Karmeli F, Rachmilewitz D, Cohen P, Fich A. Effect of chronic nicotine administration on trinitrobenzene sulphonic acid-induced colitis. Eur J Gastroenterol Hepatol. 1998;10:1013–1019
  16. Sykes AP, Brampton C, Klee S, Chander CL, Whelan C, Parsons ME. An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease. Inflamm Res. 2000;49:311–319
  17. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, Verdu EF, Collins SM. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology. 2006;131:1122–1130
  18. Thomas GA, Pullan RD, Zijlstra FJ, Rankin BJ, Russell MA, Feyerabend C, et al. Effect of nicotine on large bowel mucus thickness, eicosanoids and faecal proteinase in ferrets. Eur J Gastroenterol Hepatol. 1997;9:179–182
  19. Zijlstra FJ, Srivastava ED, Rhodes M, van Dijk AP, Fogg F, Samson HJ, et al. Effect of nicotine on rectal mucus and mucosal eicosanoids. Gut. 1994;35:247–251
  20. Van Dijk JP, Madretsma GS, Keuskamp ZJ, Zijlstra FJ. Nicotine inhibits cytokine synthesis by mouse colonic mucosa. Eur J Pharmacol. 1995;278:R11–R12
  21. Galitovskiy V, Qian J, Chernyavsky AI, Marchenko S, Gindi V, Edwards RA, et al. Cytokine-induced alterations of {alpha}7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- versus Th2-mediated colitis. J Immunol. 2011;187:2677–2687
  22. Snoek SA, Verstege MI, van der Zanden EP, Deeks N, Bulmer DC, Skynner M, et al. Selective alpha7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br J Pharmacol. 2010;160:322–333
  23. Hegazi RA, Rao KN, Mayle A, Sepulveda AR, Otterbein LE, Plevy SE. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med. 2005;202:1703–1713
  24. Sheikh SZ, Hegazi RA, Kobayashi T, Onyiah JC, Russo SM, Matsuoka K, et al. An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol. 2011;186:5506–5513
  25. Takagi T, Naito Y, Mizushima K, Akagiri S, Suzuki T, Hirata I, et al. Inhalation of carbon monoxide ameliorates TNBS-induced colitis in mice through the inhibition of TNF-alpha expression. Dig Dis Sci. 2010;55:2797–2804
  26. Ko JK, Cho CH. The diverse actions of nicotine and different extracted fractions from tobacco smoke against hapten-induced colitis in rats. Toxicol Sci. 2005;87:285–295
  27. Takamura T, Harama D, Matsuoka S, Shimokawa N, Nakamura Y, Okumura K, et al. Activation of the aryl hydrocarbon receptor pathway may ameliorate dextran sodium sulfate-induced colitis in mice. Immunol Cell Biol. 2010;88:685–689
  28. Benson JM, Shepherd DM. Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn's disease. Toxicol Sci. 2011;120:68–78
  29. Galeazzi F, Blennerhassett PA, Qiu B, O'Byrne PM, Collins SM. Cigarette smoke aggravates experimental colitis in rats. Gastroenterology. 1999;117:877–883
  30. Chow JY, Ma L, Cho CH. An experimental model for studying passive cigarette smoking effects on gastric ulceration. Life Sci. 1996;58:2415–2422
  31. Guo X, Ko JK, Mei QB, Cho CH. Aggravating effect of cigarette smoke exposure on experimental colitis is associated with leukotriene B(4) and reactive oxygen metabolites. Digestion. 2001;63:180–187
  32. Guo X, Wang WP, Ko JK, Cho CH. Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats. Gastroenterology. 1999;117:884–892
  33. Guo X, Liu ES, Ko JK, Wong BC, Ye Y, Lam S, et al. Protective role of cyclooxygenase inhibitors in the adverse action of passive cigarette smoking on the initiation of experimental colitis in rats. Eur J Pharmacol. 2001;411:193–203
  34. Sun YP, Wang HH, He Q, Cho CH. Effect of passive cigarette smoking on colonic alpha7-nicotinic acetylcholine receptors in TNBS-induced colitis in rats. Digestion. 2007;76:181–187
  35. Ko JK, Sham NF, Guo X, Cho CH. Beneficial intervention of experimental colitis by passive cigarette smoking through the modulation of cytokines in rats. J Investig Med. 2001;49:21–29
  36. Liu ES, Ye YN, Shin VY, Yuen ST, Leung SY, Wong BC, et al. Cigarette smoke exposure increases ulcerative colitis-associated colonic adenoma formation in mice. Carcinogenesis. 2003;24:1407–1413
  37. Liu ES, Ye YN, Shin VY, Wu WK, Wong BC, Cho CH. Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice. Cancer Invest. 2007;25:750–757
  38. D'hulst AI, Vermaelen KY, Brusselle GG, Joos GF, Pauwels RA. Time course of cigarette smoke-induced pulmonary inflammation in mice. Eur Respir J. 2005;26:204–213
  39. Verschuere S, Bracke KR, Demoor T, Plantinga M, Verbrugghe P, Ferdinande L, et al. Cigarette smoking alters epithelial apoptosis and immune composition in murine GALT. Lab Invest. 2011;91:1056–1067
  40. Eliakim R, Karmeli F. Divergent effects of nicotine administration on cytokine levels in rat small bowel mucosa, colonic mucosa, and blood. Isr Med Assoc J. 2003;5:178–180
  41. Martey CA, Baglole CJ, Gasiewicz TA, Sime PJ, Phipps RP. The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2005;289:L391–L399
  42. Lawrence BP, Kerkvliet NI. Role of altered arachidonic acid metabolism in 2,3,7, 8-tetrachlorodibenzo-p-dioxin-induced immune suppression in C57Bl/6 mice. Toxicol Sci. 1998;42:13–22
  43. Rickert RR, Carter HW. The “early” ulcerative lesion of Crohn's disease: correlative light- and scanning electron-microscopic studies. J Clin Gastroenterol. 1980;2:11–19
  44. Fujimura Y, Kamoi R, Iida M. Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. Gut. 1996;38:724–732
  45. Faux SP, Tai T, Thorne D, Xu Y, Breheny D, Gaca M. The role of oxidative stress in the biological responses of lung epithelial cells to cigarette smoke. Biomarkers. 2009;14(Suppl. 1):90–96
  46. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421:384–388
  47. Ingram JR, Rhodes J, Evans BK, Thomas GA. Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterol Res Pract. 2008;2008:237185
  48. Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol. 2004;2:41–48
  49. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004;18:481–496
  50. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–1233
  51. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807–1816
  52. Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case–control study. Gastroenterology. 2006;130:1941–1949
  53. Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology. 2000;47:57–70
  54. Nikfar S, Ehteshami-Ashar S, Rahimi R, Abdollahi M. Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clin Ther. 2010;32:2304–2315
  55. McGrath J, McDonald JW, Macdonald JK. Transdermal nicotine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2004;CD004722
  56. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–462
  57. Tracey KJ. Understanding immunity requires more than immunology. Nat Immunol. 2010;11:561–564
  58. Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, et al. Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology. 2011;141:237–248
  59. McGilligan VE, Wallace JM, Heavey PM, Ridley DL, Rowland IR. Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm Bowel Dis. 2007;13:108–115
  60. Targan SR, Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev. 2005;206:296–305

PII: S1873-9946(11)00256-X

doi: 10.1016/j.crohns.2011.09.006

Journal of Crohn's and Colitis
Volume 6, Issue 1 , Pages 1-12 , February 2012

Article Tools

* Image Usage & Resolution